Neuralbase AI flags going-concern, zero revenue, negative cash and internal control weakness

Neuralbase AI Ltd. (PINK: VIRA)

Quick read - what's happening inside:
Management turnover and corporate restructurings continued (asset purchase/unwind described). The company reported no revenue, a growing working-capital deficit, and continuing net losses but raised limited cash via notes and a small stock sale. The SEC filing discloses a going-concern qualification and a material weakness in internal controls.

Key facts & statistics (as reported)
* Revenues: $0 for the three and six months ended June 30, 2025 (and 2024).
* Net loss (3 months ended 6/30/2025): $(133,270).
* Net loss (6 months ended 6/30/2025): $(154,667).
* Operating expenses (3 months): $126,683; (6 months): $143,121.
* Interest expense (3 months): $(6,587); (6 months): $(11,546).
* Loss on acquisition of intangible assets: $720,000 (recorded in 2024, driving the prior-year loss).
* Weighted average common shares (basic & diluted): 41,589,708 (3 months); 45,944,824 (6 months).
* Net loss per share (basic & diluted): $(0.00) (3 months); $(0.00) (6 months) - prior-year per-share losses were larger (e.g., $(3.65) for comparable prior period reported).
* Total current liabilities (6/30/2025): $721,764; Total liabilities: $767,764.
* Notes payable (current): $202,485; Notes payable, net of debt discount: $46,000 (total promissory notes reported $248,485).
* Total assets: $0 (reported as of June 30, 2025).
* Total stockholders' deficit: $(767,764); Accumulated deficit: $(4,120,024).
* Additional paid-in capital: $3,345,131 (up from $3,255,090 at 12/31/2024).
* Common shares issued & outstanding (as of Aug 14, 2025): 59,790,183.
* Cash - statement shows Cash, end of period: $(95,900) and Net increase in cash (6 months): $(95,900).
* Cash flows from operating activities (6 months): Net cash used $(155,346); cash provided by financing activities: $59,446 (proceeds from notes payable).
* Going concern: Company discloses substantial doubt about ability to continue as a going concern.
* Internal controls: Management concluded disclosure controls and internal control over financial reporting were not effective; a material weakness exists.

What's happening inside - governance & transactions
* Multiple officer & director changes noted (resignations and appointments in 2023-2024).
* The company executed an Unwind Agreement (May 16, 2024) and a Purchase Agreement for AI assets ("Multidoc AI") paid with 9,000,000 Series A Preferred Stock (conversion terms disclosed elsewhere: 1-for-50 conversion).
* On Jan 24, 2025 a shareholder converted 1,000,000 Series A preferred into 50,000,000 common shares; during H1 2025 the company sold 9,590,000 common shares for $95,500 cash.

Positive aspects (income statement & financing)
* Net loss narrowed materially vs. the prior-year comparable periods (driven primarily by absence of the prior-year $720,000 loss on acquisition of intangible assets).
* The company raised cash via issuance of notes ($59,446 in H1 2025) and sold common shares for $95,500 during the period - incremental liquidity steps.
* Additional paid-in capital increased by ~$90,041 during the period (from $3,255,090 to $3,345,131).

Negative aspects (income statement & financial condition)
* No revenue reported in either period - zero top line for 2025 and 2024.
* Operating expenses increased sharply (3-month OPEX: $126,683 vs $6,275 prior-year) - management attributes much of this to wages paid to a former CEO.
* Consistent net losses and negative operating cash flow (Net cash used in operations H1 2025: $(155,346)).
* Reported cash at period end is negative $(95,900) - indicates critical liquidity stress or reporting of overdraft/negative bank balance.
* Total assets reported as $0 while liabilities are $767,764 - working-capital deficit and stockholders' deficit $(767,764).
* Material weakness in internal controls and limited finance personnel - risk of misstatement and weak disclosure controls.
* Heavy reliance on short-term promissory notes (many due on demand) and related-party advances ($80,680).
* Potential governance/dilution risk from convertible preferred terms (large conversion ratio disclosed in notes; conversion activity has dramatically increased common shares outstanding).

Bottom line / near-term watch items
* Immediate priority: secure financing or revenue (company states it intends to seek private equity or licensing revenue). Without new capital, operations are at risk given negative cash and zero reported assets.
* Watch: cash receipts, changes in liabilities (notes due), any monetization/licensing of the Multidoc AI assets, and remediation of internal-control weaknesses.
* Governance risk: preferred-stock conversion mechanics and prior rapid share issuance/dilution are material for existing shareholders.

If you want, I can convert this into a short investor alert or a one-page PDF with the most critical numbers highlighted.